RxDoctor Payments Data

Maheen Malik, MD

Neurology · Saint Louis, MONPI 1205834033

Payments from drug & device makers

$37,675in general payments, 2019–2025

Across 571 payments — averaging $65.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$11K
  • Novartis$9K
  • Neurocrine Biosciences, Inc.$4K
  • AbbVie$2K
  • Avanir Pharmaceuticals, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $9K from 52 others

What the payments were for

  • Speaking & faculty fees$6254%
  • Food & beverage$13,64096%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.43$10,603
Novartis62$8,863
Neurocrine Biosciences, Inc.36$4,319
AbbVie(2 entities)89$1,607
Avanir Pharmaceuticals, Inc.2$1,513
Teva Pharmaceuticals USA, Inc.47$1,438
Livanova USA, Inc.8$939
Ares Trading SA10$850
Supernus Pharmaceuticals, Inc.11$703
Acadia Pharmaceuticals Inc7$623
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$533
Biogen28$425
Pfizer23$369
Otsuka America Pharmaceutical, Inc.6$345
Otsuka Pharmaceutical Development & Commercialization, Inc.3$325
Sunovion Pharmaceuticals Inc.6$314
UCB, Inc.14$292
Alkermes, Inc.10$287
Genentech USA, Inc.9$284
Sanofi8$245
Kyowa Kirin, Inc.9$242
Eisai Inc.13$223
SK Life Science, Inc.12$199
Lundbeck LLC10$191
Amgen9$176
Axsome Therapeutics, Inc.4$164
E.r. Squibb & Sons, L.L.C.2$149
Takeda Pharmaceuticals U.S.A., Inc.3$142
Amneal Pharmaceuticals LLC6$117
AstraZeneca(2 entities)7$117
Argenx US, Inc.5$109
Bristol Myers Squibb5$98
Neurelis, Inc.5$89
Johnson & Johnson4$83
Grifols USA, LLC5$79
Vanda Pharmaceuticals Inc.3$58
Biohaven Pharmaceutical Holding Company Ltd.4$57
Ipsen Biopharmaceuticals, Inc3$54
Corium, LLC4$45
Neos Therapeutics, LP2$35
Avion Pharmaceuticals2$31
Haemonetics Corporation1$31
Validus Pharmaceuticals LLC2$29
Biohaven Pharmaceuticals, Inc.1$25
Springworks Therapeutics, Inc.1$24
Acorda Therapeutics, Inc1$24
Luye Pharma (USA) Ltd.1$22
Jazz Pharmaceuticals Inc.1$21
Greenwich Biosciences, Inc.1$20
Collegium Pharmaceutical, Inc.1$19
Upsher-smith Laboratories LLC1$19
GE HealthCare1$19
Noven Therapeutics, LLC1$16
Lilly USA, LLC1$16
Idorsia Pharmaceuticals US Inc1$14
Tanabe Pharma America, Inc.1$14
Genentech, Inc.1$13
Indivior Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,675 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$89,013
Medicare patients
342
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant23$65,141
QuliptaAtogepant21$34,724
Nurtec OdtRimegepant Sulfate11$18,766
EliquisApixaban19$12,005
Dihydroergotamine Mesylate11$10,045
Rivastigmine15$3,119
Levetiracetam89$3,026
Memantine Hcl ErMemantine Hcl33$2,385
Memantine Hcl96$2,287
Divalproex Sodium60$1,169
Zonisamide18$1,004
Oxcarbazepine23$976
Gabapentin75$975
Donepezil Hcl120$925
Pyridostigmine Bromide11$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,607$99,86544 claims
PfizerNurtec Odt, Eliquis$369$30,77130 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$117$1,49624 claims
Upsher-smith Laboratories LLCTopiramate$19$36745 claims
Lilly USA, LLCOlanzapine$16$9213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →